Agendia

View the latest OncLive interview with Joyce O’Shaughnessy, MD, as she discusses data she presented at #ASCO24 – highlighting the impact of MammaPrint High 1 and High 2 status on 3-year RFS in patients with early-stage HR+, HER2-negative who received adjuvant chemotherapy with either a taxane plus cyclophosphamide (TC) or anthracycline plus a taxane and cyclophosphamide (ATC). Watch the full interview here: https://lnkd.in/eDWF2n-r #BreastCancer #Oncology

Happy Fourth of July from all of us at Agendia! Today, we celebrate the spirit of innovation and progress that defines our nation. Here's to freedom, opportunity, and the pursuit of a brighter future for all. Wishing everyone a safe and joyful Independence Day! #IndependenceDay #FourthOfJuly

Honored to be working with Learn Look Locate on sharing the importance of genomics in breast cancer treatment.

💻LIVE WEBINAR TOMORROW: Join Dr. William Audeh Tuesday June 18th during this one-hour live webinar as he reviews new MammaPrint + BluePrint data that was recently presented at ASCO 2024. Register today: https://ow.ly/hrGA50Sfx23

We’re pleased to share that Agendia CMO, William Audeh, MD, MS is featured in May’s issue of ONCOLife by Health and Pharma. Dr. Audeh discussed a variety of topics on the subject of genomic testing in breast cancer. Some discussion topics include: · The cruciality of genetic testing in oncology treatment design, preventing resistance, and influencing success and cure rates · How the integration of MammaPrint® and BluePrint® tests into clinical practice has transformed the decision-making process · How a fast turnaround can impact the treatment planning process · And more! Read Dr. Audeh’s full interview at: https://lnkd.in/gC_6DucS

Excited to share insights from the Dutch Bossche Congress! Our latest research on neoadjuvant chemo and MammaPrint High 2 tumors unveils groundbreaking findings. Dive into the data: https://lnkd.in/gmJUvbSg #BreastCancerResearch #PrecisionMedicine

Harald Müller-Huesmann of St. Josef Brothers Hospital Paderborn, Germany will present a poster at #ASCO24 titled “Cost consequence model of the MammaPrint® (70-gene signature) and 21-gene signature in Patients with primary HR+ HER2-, N1 early-stage breast cancer in Germany.” The Agendia team is pleased to add this study to our already robust library of clinical studies demonstrating Agendia’s MammaPrint effectiveness in providing reliable guidance for therapeutic considerations in early-stage breast cancer. View the poster here: https://lnkd.in/gqBGkbnU #Oncology #BreastCancer #MammaPrint

Erin Cobain, MD, will present new #FLEX data at #ASCO24 on characterizing the immune biology of MammaPrint® High Risk tumors. “There is a great need for biomarkers beyond PD-L1 and tumor mutational burden that may predict clinical benefit from immunotherapy-based treatments. The recent CheckMate 7FL and KEYNOTE-756 studies demonstrated that there is a subset of patients with HR+HER2- early breast cancer that will benefit from immunotherapy, as both trials demonstrated an improvement in likelihood of pathologic complete response rates for those patients receiving neoadjuvant chemo-immunotherapy compared to chemotherapy alone,” said Dr. Cobain. “However, we are aiming to take this a step further and refine the biomarkers that will allow for us to identify those patients most likely to benefit from this approach and avoid overtreatment. This is particularly important given the potential serious toxicities that can result from immunotherapy treatment.” Attend Dr. Cobain’s Oral Abstract Presentation on June 3rd from 3-6PM CT. Read the release: https://lnkd.in/gRABtHnp #Oncology #BreastCancer #MammaPrint

Celebrating survivors on #CancerSurvivorsDay, honoring their strength, resilience, and unwavering hope. Their journey, marked by courage in the face of adversity, inspires us all. Together, we stand in solidarity, offering support and encouragement as they continue to thrive beyond cancer. Their stories are a testament to the power of the human spirit and serve as a beacon of hope for those currently battling the disease. Let us unite in celebration, affirming our commitment to supporting survivors and advocating for improved care and research initiatives. Today and every day, we honor their remarkable journey of triumph and resilience.

Additional data supporting MammaPrint® utility in treatment selection will be presented in a #ASCO24 poster by other investigators titled “Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancer Closely Resembles Triple Negative Breast Cancer: Results from Gene Expression Data from the ISPY2 Trial” [Rios-Hoyo, A., et al.]. Attend the poster session presentation on June 2nd from 9:00am – 12:00pm CT. View the poster here: https://lnkd.in/gFYypyMQ #ASCO24 #oncology #breastcancer